Vantaa

Researchers are evaluating the safety, tolerability, and effectiveness of the drug Pumitamig alone or combined with Ipilimumab or Cabozantinib in adults with advanced Renal Cell Carcinoma RCC. This study focuses on participants with locally advanced, unresectable, or metastatic RCC, including both clear cell and non-clear cell types in the initial phase, and only clear cell RCC in later phases. The trial is conducted in phases 1 and 2 to gather detailed information about these treatments. Participants receive specified doses of Pumitamig, Ipilimumab, and Cabozantinib according to study group assignments. The study uses a randomized, parallel design with multiple experimental arms to compare these treatments alone or in combination. Participants may be assigned to one of several groups receiving different drug combinations, with dosing schedules specified by the protocol. During the study, participants undergo regular safety monitoring for adverse events and serious adverse events for up to approximately two years after treatment ends. Effectiveness is assessed by measuring tumor response using established criteria and tracking progression-free survival and duration of response over time. The study includes ongoing evaluations and follow-up visits to observe treatment impact and monitor participant health until the studys completion in 2031.

The aging population worldwide is growing rapidly, with more elderly people retaining their natural teeth than before. Maintaining oral health is crucial for older adults, as poor dental condition can lead to complications like infections and reduced quality of life. This research evaluates the use of antibacterial photodynamic therapy aPDT combined with antibacterial blue light aBL using the Lumoral device, alongside regular dental care, to help improve oral hygiene in elderly people living at home or in care homes. Participants will be divided into two groups one group will use the Lumoral Treatment device at home combined with standard oral hygiene methods, while the other group will follow only standard oral hygiene practices. The Lumoral device uses a photosensitive mouthwash activated by light to target harmful bacteria in dental plaque. The study will last 9 months, during which participants will receive regular dental appointments and instructions on oral care. Throughout the study, participants will be monitored with dental examinations measuring bleeding on probing, plaque levels, periodontal pocket depth, oral bacterial flora, mouth dryness, and quality of life related to oral health. Safety will be tracked by recording any adverse events. The study aims to assess how the Lumoral Treatment affects oral hygiene, inflammation, and mouth dryness in elderly individuals over this period.

This observational study explores how anterior open bite malocclusion affects daily life, evaluates the effectiveness of its orthodontic treatment, and examines the burden of care caused by the treatment. The research is led by the University of Helsinki and focuses on understanding treatment outcomes and patient impact over time. Participants with a clinical diagnosis of anterior open bite malocclusion, either past or present, are observed without receiving experimental treatments. The study mainly tracks natural outcomes related to the condition and its management, focusing on stability and patient experience over approximately one year. During the study, researchers measure overbite and occlusal contacts, monitor treatment time, and assess temporomandibular disorders TMD over an average period of one year. Participants may be asked to undergo clinical evaluations and provide information about their daily functioning and treatment impact. The total duration of observation allows for evaluation of treatment stability and the conditions effect on daily life.